viewAvalon GloboCare Corp

Avalon GloboCare and Adial Pharmaceuticals form strategic collaboration to distribute COVID-19 point-of-care antibody rapid test devices

The FDA has issued an emergency use authorization for the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device device, as well as the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device 

Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for both tests

Avalon GloboCare Corp (NASDAQ:AVCO) and Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced Thursday the formation of a strategic collaboration for the global distribution of coronavirus (COVID-19) point-of-care antibody rapid test devices.

The Assure/FaStep COVID-19 IgG/IgM Rapid Test Device is the first serology (antibody) POC test for COVID-19 using fingerstick blood samples approved by the US Food and Drug Administration (FDA).

The FDA has issued an emergency use authorization (EUA) for the test device as well as for the Assure/EcoStep COVID-19 IgG/IgM Rapid Test Device. 

READ: Avalon GloboCare launches its new MSC platform as a potential therapy for coronavirus (COVID-19)

Under the agreement, Adial has granted Avalon non-exclusive, sub-distribution rights worldwide for both tests, according to a statement. 

As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional. 

The FaStep COVID-19 IgG/IgM Rapid Test Devices are lateral flow assay, 10-minute POC test devices for the qualitative detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in fingerstick whole blood, venous whole blood, serum, and plasma. During testing, the specimen reacts with antigen-coated particles in the test cassette after droplets of blood from the subject are placed on the cassette's coated membrane.

"We believe there is significant market potential for these differentiated test kits, as these tests are able to detect IgG antibodies at a 98.6% accuracy and IgM antibodies at a 92.9% accuracy and provide results within 10 minutes," said Avalon CEO Dr David Jin in a statement. "Our goal is to leverage our international distribution network and channel partners to bring the product to market globally."

William Stilley, CEO of Adial, noted that Avalon has an established global distribution network that will facilitate further sales of the COVID-19 test devices worldwide. 

“The rapid proliferation of COVID-19 around the world has driven demand for SARS-CoV-2 detection, and a widespread need for rapid antibody testing,” said Stilley. “We look forward to working with Avalon in order to help meet the global demand for rapid result COVID-19 serology testing."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Avalon GloboCare Corp

Price: 1.22 USD

Market: NASDAQ
Market Cap: $99.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...


Avalon GloboCare preparing to begin its first in-human clinical trial to...

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr David Jin updated investors on the progress of its research and development programs in cell therapy and Covid-19-related initiatives. Dr Jin explains how the New York-based group is getting reading to initiate its first in-human clinical c in the...

on 08/25/2020

2 min read